hVEGFA/hPD-1/hPD-L1

Nomenclature

C57BL/6JSmo-Vegfatm1(hVEGFA)Pdcd1tm1(hPDCD1)Cd274tm1(hPD-L1)Smoc

Cat. NO.

NM-XA-242143

Strain State

Repository Live

Export PDF

Model Description

The hPD-1/hPD-L1(NM-HU-00100) was crossed with hVEGFA(NM-HU-2000028) to generate hVEGFA/hPD-1/hPD-L1 mice.

Validation Data

image.png

Fig.1 Body weight were measured twice a week of hVEGFA/hPD-1/hPD-L1 (C57BL/6) mice (n=8). (A）Body weight. (B) Body weight change.

image.png

Fig.2 Tumor volume were measured twice a week of hVEGFA/hPD-1/hPD-L1 (C57BL/6) mice. (A) Tumor volume. (B) Relative tumor volume.

MC38-hVEGFA (1×106) were inoculated subcutaneously into hVEGFA/hPD-1/hPD-L1 (C57BL/6) mice (male, 8-week-old, n=8). 

image.png

Fig.3 In vivo efficacy assessment of Ivonescimab in hVEGFA/hPD-1/hPD-L1 (C57BL/6) (NM-XA-242143) mice bearing MC38-hVEGFA/hPD-L1 syngeneic tumor.

Detection of human VEGFA expression in MC38-hVEGFA/hPD-L1 tumor by ELISA (n=2). 

image.png

Fig.4 In vivo efficacy assessment of Ivonescimab in hVEGFA/hPD-1/hPD-L1 (C57BL/6) (NM-XA-242143) mice bearing MC38-hVEGFA/hPD-L1 syngeneic tumor.

Detection of human PD-L1 expression in MC38-hVEGFA/hPD-L1 tumor by FACS (n=2).

image.png

Fig.5 In vivo efficacy assessment of Ivonescimab in hVEGFA/hPD-1/hPD-L1 (C57BL/6) (NM-XA-242143) mice bearing MC38-hVEGFA/hPD-L1 syngeneic tumor.

Body weight were measured twice a week of hVEGFA/hPD-1/hPD-L1 (C57BL/6) mice (female, 13-week-old, n=8). (A）Body weight. (B) Body weight change.

image.png

Fig.6 In vivo efficacy assessment of Ivonescimab in hVEGFA/hPD-1/hPD-L1 (C57BL/6) (NM-XA-242143) mice bearing MC38-hVEGFA/hPD-L1 syngeneic tumor.

Tumor volume were measured twice a week of hVEGFA/hPD-1/hPD-L1 (C57BL/6) mice. MC38-hVEGFA/hPD-L1 (1×106) were inoculated subcutaneously into hVEGFA/hPD-1/hPD-L1 (C57BL/6) mice (female, 13-week-old, n=8). (A) Tumor volume. (B) Relative tumor volume.

image.png

Fig.7 In vivo efficacy assessment of Ivonescimab in hVEGFA/hPD-1/hPD-L1 (C57BL/6) (NM-XA-242143) mice bearing MC38-hVEGFA/hPD-L1 syngeneic tumor.

Flow cytometry analysis of tumor-infiltrating lymphocytes (TILs) from MC38-hVEGFA/hPD-L1 tumor by FACS. Tumor-infiltrating lymphocytes (TILs) were collected to carry out an immunophenotypic analysis by flow cytometry (n=4). According to flow cytometric analysis, post-treatment led to a significant increase in the proportion of T cells, and a substantial reduction in the proportion of myeloid cells.


You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Workshop：Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more